We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| AbbVie Inc | NYSE:ABBV | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 1.66 | 0.99% | 169.55 | 170.365 | 168.22 | 168.98 | 4,084,107 | 01:00:00 |
From Apr 2019 to Apr 2024
By Josh Beckerman
Evolus Inc. shares fell 31% to $3.65 following a non-binding initial decision against the company in a U.S. International Trade Commission dispute concerning Botox rival Jeuveau.
Botox maker Allergan, which is now a unit of AbbVie Inc., and Medy-Tox Inc. filed a complaint in January 2019 against Evolus and Daewoong Pharmaceutical Co.
Evolus said Monday that "we strongly disagree with the initial determination and we look forward to the full Commission's Final Determination" targeted for Nov. 6, and said it will petition the ITC to review the initial determination.
Evolus also said Daewoong will invest $40 million in the company, strengthening its balance sheet.
Mizuho, SunTrust Robinson Humphrey and HC Wainwright & Co. lowered their Evolus price targets.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
July 07, 2020 14:55 ET (18:55 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year AbbVie Chart |
1 Month AbbVie Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
